Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.

Philippe Armand, Haesook T. Kim, Brent R. Logan, Zhiwei Wang, Edwin P. Alyea, Matt E. Kalaycio, Richard Maziarz, Joseph H. Antin, Robert J. Soiffer, Daniel J. Weisdorf, J. Douglas Rizzo, Mary M. Horowitz, Wael Saber

Research output: Contribution to journalArticle

277 Citations (Scopus)

Abstract

Because the outcome of allogeneic hematopoietic cell transplantation (HCT) is predominantly influenced by disease type and status, it is essential to be able to stratify patients undergoing HCT by disease risk. The Disease Risk Index (DRI) was developed for this purpose. In this study, we analyzed 13,131 patients reported to the Center for International Blood and Marrow Transplant Research who underwent HCT between 2008 and 2010. The DRI stratified patients into 4 groups with 2-year overall survival (OS) ranging from 64% to 24% and was the strongest prognostic factor, regardless of age, conditioning intensity, graft source, or donor type. A randomly selected training subgroup of 9849 patients was used to refine the DRI, using a multivariable regression model for OS. This refined DRI had improved prediction ability for the remaining 3282 patients compared with the original DRI or other existing schemes. This validated and refined DRI can be used as a 4- or 3-group index, depending on the size of the cohort under study, for prognostication; to facilitate the interpretation of single-center, multicenter, or registry studies; to adjust center outcome data; and to stratify patients entering clinical trials that enroll patients across disease categories.

Original languageEnglish (US)
Pages (from-to)3664-3671
Number of pages8
JournalBlood
Volume123
Issue number23
DOIs
StatePublished - 2014

Fingerprint

Stem Cell Transplantation
Stem cells
Cell Transplantation
Transplants
Survival
Grafts
Registries
Blood
Cohort Studies
Bone Marrow
Tissue Donors
Clinical Trials
Research

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Armand, P., Kim, H. T., Logan, B. R., Wang, Z., Alyea, E. P., Kalaycio, M. E., ... Saber, W. (2014). Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood, 123(23), 3664-3671. https://doi.org/10.1182/blood-2014-01-552984

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. / Armand, Philippe; Kim, Haesook T.; Logan, Brent R.; Wang, Zhiwei; Alyea, Edwin P.; Kalaycio, Matt E.; Maziarz, Richard; Antin, Joseph H.; Soiffer, Robert J.; Weisdorf, Daniel J.; Rizzo, J. Douglas; Horowitz, Mary M.; Saber, Wael.

In: Blood, Vol. 123, No. 23, 2014, p. 3664-3671.

Research output: Contribution to journalArticle

Armand, P, Kim, HT, Logan, BR, Wang, Z, Alyea, EP, Kalaycio, ME, Maziarz, R, Antin, JH, Soiffer, RJ, Weisdorf, DJ, Rizzo, JD, Horowitz, MM & Saber, W 2014, 'Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.', Blood, vol. 123, no. 23, pp. 3664-3671. https://doi.org/10.1182/blood-2014-01-552984
Armand, Philippe ; Kim, Haesook T. ; Logan, Brent R. ; Wang, Zhiwei ; Alyea, Edwin P. ; Kalaycio, Matt E. ; Maziarz, Richard ; Antin, Joseph H. ; Soiffer, Robert J. ; Weisdorf, Daniel J. ; Rizzo, J. Douglas ; Horowitz, Mary M. ; Saber, Wael. / Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. In: Blood. 2014 ; Vol. 123, No. 23. pp. 3664-3671.
@article{83a79bb5d4594f21999275b5475efdeb,
title = "Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.",
abstract = "Because the outcome of allogeneic hematopoietic cell transplantation (HCT) is predominantly influenced by disease type and status, it is essential to be able to stratify patients undergoing HCT by disease risk. The Disease Risk Index (DRI) was developed for this purpose. In this study, we analyzed 13,131 patients reported to the Center for International Blood and Marrow Transplant Research who underwent HCT between 2008 and 2010. The DRI stratified patients into 4 groups with 2-year overall survival (OS) ranging from 64{\%} to 24{\%} and was the strongest prognostic factor, regardless of age, conditioning intensity, graft source, or donor type. A randomly selected training subgroup of 9849 patients was used to refine the DRI, using a multivariable regression model for OS. This refined DRI had improved prediction ability for the remaining 3282 patients compared with the original DRI or other existing schemes. This validated and refined DRI can be used as a 4- or 3-group index, depending on the size of the cohort under study, for prognostication; to facilitate the interpretation of single-center, multicenter, or registry studies; to adjust center outcome data; and to stratify patients entering clinical trials that enroll patients across disease categories.",
author = "Philippe Armand and Kim, {Haesook T.} and Logan, {Brent R.} and Zhiwei Wang and Alyea, {Edwin P.} and Kalaycio, {Matt E.} and Richard Maziarz and Antin, {Joseph H.} and Soiffer, {Robert J.} and Weisdorf, {Daniel J.} and Rizzo, {J. Douglas} and Horowitz, {Mary M.} and Wael Saber",
year = "2014",
doi = "10.1182/blood-2014-01-552984",
language = "English (US)",
volume = "123",
pages = "3664--3671",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "23",

}

TY - JOUR

T1 - Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.

AU - Armand, Philippe

AU - Kim, Haesook T.

AU - Logan, Brent R.

AU - Wang, Zhiwei

AU - Alyea, Edwin P.

AU - Kalaycio, Matt E.

AU - Maziarz, Richard

AU - Antin, Joseph H.

AU - Soiffer, Robert J.

AU - Weisdorf, Daniel J.

AU - Rizzo, J. Douglas

AU - Horowitz, Mary M.

AU - Saber, Wael

PY - 2014

Y1 - 2014

N2 - Because the outcome of allogeneic hematopoietic cell transplantation (HCT) is predominantly influenced by disease type and status, it is essential to be able to stratify patients undergoing HCT by disease risk. The Disease Risk Index (DRI) was developed for this purpose. In this study, we analyzed 13,131 patients reported to the Center for International Blood and Marrow Transplant Research who underwent HCT between 2008 and 2010. The DRI stratified patients into 4 groups with 2-year overall survival (OS) ranging from 64% to 24% and was the strongest prognostic factor, regardless of age, conditioning intensity, graft source, or donor type. A randomly selected training subgroup of 9849 patients was used to refine the DRI, using a multivariable regression model for OS. This refined DRI had improved prediction ability for the remaining 3282 patients compared with the original DRI or other existing schemes. This validated and refined DRI can be used as a 4- or 3-group index, depending on the size of the cohort under study, for prognostication; to facilitate the interpretation of single-center, multicenter, or registry studies; to adjust center outcome data; and to stratify patients entering clinical trials that enroll patients across disease categories.

AB - Because the outcome of allogeneic hematopoietic cell transplantation (HCT) is predominantly influenced by disease type and status, it is essential to be able to stratify patients undergoing HCT by disease risk. The Disease Risk Index (DRI) was developed for this purpose. In this study, we analyzed 13,131 patients reported to the Center for International Blood and Marrow Transplant Research who underwent HCT between 2008 and 2010. The DRI stratified patients into 4 groups with 2-year overall survival (OS) ranging from 64% to 24% and was the strongest prognostic factor, regardless of age, conditioning intensity, graft source, or donor type. A randomly selected training subgroup of 9849 patients was used to refine the DRI, using a multivariable regression model for OS. This refined DRI had improved prediction ability for the remaining 3282 patients compared with the original DRI or other existing schemes. This validated and refined DRI can be used as a 4- or 3-group index, depending on the size of the cohort under study, for prognostication; to facilitate the interpretation of single-center, multicenter, or registry studies; to adjust center outcome data; and to stratify patients entering clinical trials that enroll patients across disease categories.

UR - http://www.scopus.com/inward/record.url?scp=84905902438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905902438&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-01-552984

DO - 10.1182/blood-2014-01-552984

M3 - Article

C2 - 24744269

AN - SCOPUS:84905902438

VL - 123

SP - 3664

EP - 3671

JO - Blood

JF - Blood

SN - 0006-4971

IS - 23

ER -